A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
China
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality Affiliated Cancer Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong Shenzhen Second People's Hospital, Shenzhen, Guangdong The First Affiliated Hospital of Xi'an Jiao Tong University, Xian, Shanxi West China Hospital，Sichuan University, Chengdu, Sichuan Age range
18 Years and older
Last updated September 2025